Multicancer blood tests have for years been hyped as a potential breakthrough in early cancer detection. But with news that one of the big names in the field, the Galleri test, failed to meet its ...

This won’t be the year Utah approves an alternative exam to replace the RISE or Aspire tests in the state public school system after the House killed the legislation Wednesday. A proposal by ...

The test costs $949 and is not federally approved. (HealthDay News) — A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it. The ...

Grail, a healthcare company seeking to help more patients detect cancer early while it can still be cured, has had a difficult five years, facing job cuts, restructuring, and a botched acquisition.

Value stream management involves people in the organization to examine workflows and other processes to ensure they are deriving the maximum value from their efforts while eliminating waste — of ...